HA-Coated and Non-HA Threads for Midface Lifting and Nasolabial Fold Correction
Evaluation of Safety and Effectiveness of APTOS Threads - Absorbable Surgical Sutures Excellence Product Line Models for Mid-face Suspension by Mini-Invasive Surgery to Temporarily Fixate the Cheek Sub-dermis in a Repositioned Site for the Treatment of Moderate to Severe Nasolabial Fold.
This randomized study compared absorbable facial lifting threads with and without a hyaluronic acid (HA) coating in 144 adults with moderate-to-severe nasolabial folds, the lines extending from the sides of the nose toward the corners of the mouth. Participants were randomly assigned in a 1:1 ratio to receive either HA-coated or non-HA threads.
Follow-up continued for six months. The main assessments evaluated adverse events through Day 30 and changes in nasolabial fold severity at Day 90. Independent evaluators assessed standardized photographs, and participants rated their aesthetic improvement and satisfaction. Additional assessments examined safety and maintenance of improvement through Day 180
研究概览
地位
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Batumi、乔治亚州、6000
- "Total Charm Piazza",15 Vakhtang Gorgasali Street
-
Tbilisi、乔治亚州、0109
- "Total Charm LTD", Orbeliani Str #18
-
Tbilisi、乔治亚州、0162
- "Total Charm Vake", 87B Zakaria Paliashvili Street
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male and female subjects, 22+ years of age.
- Subjects who desire cheek lifting to correct age-related wrinkles in the mid-face as recommended by the treating investigator.
- Subject received a rating, in each cheek, by Investigator of at least Grade 3 or Grade 4 for wrinkling of the NLF in the mid-face according to the WSRS.
- If a woman is of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), then she must have a confirmed negative urine pregnancy test result at screening. If treatment is not provided at the screening visit, a negative urine pregnancy test result is required within 7 days before treatment.
- If a woman of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), subject confirms she will utilize at least one form of contraception throughout the duration of the study (6 months).
- Subjects who are able to understand the study requirements, including the obligation not to receive any other facial procedures or treatments affecting mid-face at any time during the study. These include procedures or treatments done at home or with a professional. Facial treatments include lasers, facial massages, and anything beyond common skincare routine.
- Subjects who are willing to participate in the study and to sign a witnessed/informed consent form.
- Subjects who are logistically able to present for all study visits and meet all study requirements.
- Subjects who are willing to complete a 30-day diary.
- Subjects who pass the pinprick and/or cotton swab facial nerve assessment
Exclusion Criteria:
- Abnormal rating in mid-face sensation, with inability to feel a 0.4 G monofilament or a cotton wisp at any site on the mid-face.
- Active acne or prominent acne scars in the treatment area.
- Active inflammatory or infectious conditions.
- Allergy or foreign body sensitivities to plastic biomaterials.
- Known bleeding disorder.
- Breast feeding, pregnant, or not on/willing to use contraception if of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile).
- Known collagen skin disorder.
- Pre-existing facial asymmetry.
- History of any device use on the mid-face in the prior 6 months (laser, Intense Pulsed Light [IPL], radiofrequency (RF), ultrasound, micro needling, micro needle RF, or cool based treatments).
- History of autoimmune or connective tissue disease.
- History of facelift, mid-face lift, lower facelift or neck lift that changes the facial structure and anchor points.
- History of fat transfer to the mid-face.
- History of injectable fillers other than temporary fillers such as HA or Radiesse to the mid-face at any time. Permanent and semi-permanent fillers are not allowed (Poly-L-lactic acids [PLLA], Sculptra).
- History of Kybella in the prior 6 months.
- History of facial trauma in the mid-face.
- History of facial surgical procedures.
- Inability to chew, puff cheek, or smile broadly.
- Metabolism irregularities.
- Receiving immunosuppressive therapy.
- Recent weight loss or intention to lose a significant amount of weight during the study period (2 body mass index [BMI] points).
- Subjects who have undergone cosmetic facial plastic surgery (with the exception of rhinoplasty or upper blepharoplasty) more than 2 years prior to enrollment, tissue grafting, or tissue lifting or augmentation with any permanent or semi-permanent filler.
- Subjects who have had temporary facial dermal filler injections below the orbital rim with HA-based fillers or Radiesse within 18 months, porcine-based collagen fillers within 24 months, or neuromodulator injections to the mid-face or lateral canthal lines, mesotherapy, or resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) within 6 months of entry in the study or who were planning to undergo any of these procedures at any time during the study.
- Subjects who have very thin skin in the mid-face region, who have a tendency to accumulate fluid in the lower eyelids, or who have large infraorbital fat pads (i.e., significant convexity or projection from the infraorbital fat pads).
- Subjects who have mid-face volume deficit due to congenital defect, trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome), inherited disease, or HIVrelated disease.
- Subjects who are included to list of vulnerable populations (pediatric, pregnant, elderly individuals with visual or hearing impairments, mentally ill subjects).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:HA-Coated P(LA/CL) Lifting Threads
Participants received absorbable poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] lifting threads coated with hyaluronic acid in a single bilateral midface procedure under local anesthesia. Five threads were placed subcutaneously on each side of the face. Visage Excellence HA, Visage Excellence Soft HA, or Nano Excellence HA threads were selected according to the planned implantation trajectory. Participants were followed for six months after implantation. |
The device consists of absorbable, multibarbed monofilament threads made from poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] and coated with non-animal-derived, non-cross-linked, medium-molecular-weight sodium hyaluronate. Manufactured by Aptos LLC, Georgia, the models used were Visage Excellence HA (190 mm), Visage Excellence Soft HA (100 mm), and Nano Excellence HA (80 mm). All models had the same number of barbs despite their different lengths and were supplied preloaded in cannulas for subcutaneous tissue repositioning. |
|
实验性的:Non-HA-Coated P(LA/CL) Lifting Threads
Participants received absorbable poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] lifting threads without hyaluronic acid coating in a single bilateral midface procedure under local anesthesia. Five threads were placed subcutaneously on each side of the face. Visage Excellence, Visage Excellence Soft, or Nano Excellence threads were selected according to the planned implantation trajectory. Participants were followed for six months after implantation. |
The device consists of absorbable, multibarbed monofilament threads made from poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] without hyaluronic acid coating. Manufactured by Aptos LLC, Georgia, the models used were Visage Excellence (190 mm), Visage Excellence Soft (100 mm), and Nano Excellence (80 mm). All models had the same number of barbs despite their different lengths and were supplied preloaded in cannulas for subcutaneous tissue repositioning. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Incidence of device and procedure related serious adverse events by Day 30 (Month 1) after the implantation procedure.
大体时间:From implantation through Day 30.
|
From implantation through Day 30.
|
|
Reduction in NLF severity at Day 90 (Month 3) after the implantation procedure in comparison with baseline grading, as assessed by blinded evaluators using the Wrinkles Severity Rating Scale (WSRS).
大体时间:Baseline and Day 90 after implantation
|
Baseline and Day 90 after implantation
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Incidence of all adverse events after implantation of threads throughout the whole study.
大体时间:through Day 180 [Month 6] after the implantation procedure
|
through Day 180 [Month 6] after the implantation procedure
|
|
Incidence of early recovery symptoms related to the treatment (threads implantation) among adverse events reported by both patients and treating physician(s)
大体时间:Up to Day 14 after the implantation procedure.
|
Up to Day 14 after the implantation procedure.
|
|
Observed values and change from baseline in WSRS
大体时间:On Day 30 and Day 180.
|
On Day 30 and Day 180.
|
|
The proportion of subjects with improvement of ≥1 WSRS score at each visit
大体时间:Days 30, 90, and 180 after implantation.
|
Days 30, 90, and 180 after implantation.
|
|
Mean GAIS value assessed by blinded evaluators with frequency of each grade and sum of improved subjects (excellent, very much improved, improved)
大体时间:On Day 30, Day 90, and Day 180
|
On Day 30, Day 90, and Day 180
|
|
Mean GAIS value assessed by subject with frequency of each grade and sum of improved subjects (excellent, very much improved, improved)
大体时间:Days 30, 90, and 180 after implantation.
|
Days 30, 90, and 180 after implantation.
|
|
Patient satisfaction with the procedure outcome assessed using the mean total Face-QTM Satisfaction with Outcome score.
大体时间:At Day 30 (Month 1), Day 90 (Month 3), and Day 180 (Month 6) after the implantation procedure.
|
At Day 30 (Month 1), Day 90 (Month 3), and Day 180 (Month 6) after the implantation procedure.
|
合作者和调查者
赞助
调查人员
- 学习椅:Anna Kadzhaya, MD、Aptos LLC, Tbilisi, Georgia.15 Givi Amilakhvari Street
出版物和有用的链接
一般刊物
- Niu Z, Zhang K, Yao W, Li Y, Jiang W, Zhang Q, Troulis MJ, August M, Chen Y, Han Y. A Meta-Analysis and Systematic Review of the Incidences of Complications Following Facial Thread-Lifting. Aesthetic Plast Surg. 2021 Oct;45(5):2148-2158. doi: 10.1007/s00266-021-02256-w. Epub 2021 Apr 5.
- Day DJ, Littler CM, Swift RW, Gottlieb S. The wrinkle severity rating scale: a validation study. Am J Clin Dermatol. 2004;5(1):49-52. doi: 10.2165/00128071-200405010-00007.
- Ziade G, Daou D, Karam D, Tsintsadze M. The third generation barbed lifting threads: Added value of hyaluronic acid. J Cosmet Dermatol. 2024 Jan;23(1):186-192. doi: 10.1111/jocd.15885. Epub 2023 Jul 19.
- Wong V. The Science of Absorbable Poly(L-Lactide-Co-epsilon-Caprolactone) Threads for Soft Tissue Repositioning of the Face: An Evidence-Based Evaluation of Their Physical Properties and Clinical Application. Clin Cosmet Investig Dermatol. 2021 Jan 13;14:45-54. doi: 10.2147/CCID.S274160. eCollection 2021.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- Excellence - 001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.